Atg7

ATG7-IN-2 is a potent inhibitor of ATG7, demonstrating an IC50 of 0.089 μM. This compound effectively inhibits the autophagy marker LC3B, making it a valuable tool for studies involving autophagy modulation. Researchers can utilize ATG7-IN-2 to investigate the role of autophagy in various biological processes and disease states.

ATG7-IN-1 is a selective inhibitor of the autophagy-related protein ATG7, exhibiting an IC50 of 62 nM. This compound interferes with autophagy processes by disrupting the function of ATG7, making it a valuable tool for research in autophagy regulation. It is particularly useful for studies investigating the role of autophagy in various diseases, including cancer and neurodegenerative disorders.

ATG7-IN-3 is a highly effective inhibitor of ATG7, exhibiting an IC50 of 0.048 μM. This compound disrupts autophagy by preventing the formation of LC3B puncta, a critical process in the autophagic pathway. Research applications include investigations into glioma and colon cancer, making it a valuable tool for studying the role of autophagy in cancer biology.

Alborixin is a potent inhibitor of the PI3K-AKT signaling pathway that promotes autophagy. It facilitates the clearance of intracellular and extracellular amyloid-β by upregulating key autophagy-related proteins such as BECN1, ATG5, and ATG7, while enhancing lysosomal activity. This mechanism yields a reduction in amyloid-β-mediated neurotoxicity, positioning Alborixin as a valuable tool for research related to Alzheimer's disease and other neurodegenerative conditions.